PMID- 37221461
OWN - NLM
STAT- MEDLINE
DCOM- 20230525
LR  - 20230526
IS  - 1471-2415 (Electronic)
IS  - 1471-2415 (Linking)
VI  - 23
IP  - 1
DP  - 2023 May 23
TI  - Predictive effect of TCED-HFV grading and imaging biomarkers on anti-VEGF therapy 
      in diabetic macular edema.
PG  - 232
LID - 10.1186/s12886-023-02973-7 [doi]
LID - 232
AB  - BACKGROUND: To evaluate the predictive effect of TCED-HFV grading and imaging 
      biomarkers on anti-vascular endothelial growth factor (anti-VEGF) treatment in 
      diabetic macular edema (DME). METHODS: 81 eyes of 81 DME patients who were 
      treated with anti-VEGF were included in this retrospective cohort study. All 
      patients underwent a comprehensive ophthalmic examination at baseline and 
      follow-up, including best-corrected visual acuity (BCVA), fundus photography, and 
      spectral domain-optical coherence tomography (SD-OCT). Baseline imaging 
      biomarkers were qualitatively and quantitatively graded according to the TCED-HFV 
      classification protocol, and DME was divided into early stage, advanced stage, 
      severe stage, and atrophy stage. RESULTS: Six months post treatment, central 
      subfield thickness (CST) in 49 eyes (60.5%) had decreased by 10% from baseline, 
      30 eyes (37.0%) had achieved CST < 300 mum, and 45 eyes (55.6%) had BCVA improved 
      by more than five letters. Multivariate regression analysis revealed that eyes 
      with baseline CST >/= 390 mum had a higher probability of >/= 10% reduction in CST 
      from baseline, and eyes with abundant hyperreflective dots (HRD) had a lower 
      probability of 10% reduction in CST (all P < 0.05). Eyes with vitreomacular 
      traction (VMT) or epiretinal membrane (ERM) at baseline were less likely to reach 
      the end point of CST < 300 mum (P < 0.05). BCVA increases of more than five 
      letters were less likely in eyes with baseline BCVA >/= 69 letters, complete or 
      partial destruction of ellipsoid zone (EZ) at baseline (all P < 0.05). TCED-HFV 
      staging was negatively correlated with BCVA at both baseline and 6 months 
      (Kendall's tau-b=-0.39 and - 0.55, all P < 0.01). TCED-HFV staging was positively 
      correlated with CST at 6 months (Kendall's tau-b = 0.19, P = 0.049) and 
      negatively correlated with the reduction of CST (Kendall's tau-b=-0.32, 
      P < 0.01). CONCLUSION: The TCED-HFV grading protocol facilitates a comprehensive 
      assessment of DME severity, standardizes the grading of multiple imaging 
      biomarkers, and predicts the anatomical and functional outcomes of anti-VEGF 
      treatment.
CI  - (c) 2023. The Author(s).
FAU - Yu, Lu
AU  - Yu L
AD  - Department of Ophthalmology, Beijing Tongren Hospital, Beijing Tongren Eye 
      Center, Capital Medical University, 1 Dongjiaominxiang Road, Beijing, 100073, 
      P.R. China.
AD  - Beijing Ophthalmology and Visual Sciences Key Laboratory, Capital Medical 
      University, Beijing, 100073, P.R. China.
AD  - Department of Ophthalmology, Aerospace Center Hospital, Peking University 
      Aerospace School of Clinical Medicine, Beijing, 100049, P.R. China.
FAU - Hao, Xiaolin
AU  - Hao X
AD  - Department of Ophthalmology, Aerospace Center Hospital, Peking University 
      Aerospace School of Clinical Medicine, Beijing, 100049, P.R. China.
FAU - Cheng, Jie
AU  - Cheng J
AD  - Department of Ophthalmology, Aerospace Center Hospital, Peking University 
      Aerospace School of Clinical Medicine, Beijing, 100049, P.R. China.
FAU - Ling, Yu
AU  - Ling Y
AD  - Department of Ophthalmology, Aerospace Center Hospital, Peking University 
      Aerospace School of Clinical Medicine, Beijing, 100049, P.R. China.
FAU - Ren, Hong
AU  - Ren H
AD  - Department of Ophthalmology, Aerospace Center Hospital, Peking University 
      Aerospace School of Clinical Medicine, Beijing, 100049, P.R. China.
FAU - Mo, Bin
AU  - Mo B
AD  - Department of Ophthalmology, Beijing Tongren Hospital, Beijing Tongren Eye 
      Center, Capital Medical University, 1 Dongjiaominxiang Road, Beijing, 100073, 
      P.R. China.
AD  - Beijing Ophthalmology and Visual Sciences Key Laboratory, Capital Medical 
      University, Beijing, 100073, P.R. China.
FAU - Liu, Wu
AU  - Liu W
AD  - Department of Ophthalmology, Beijing Tongren Hospital, Beijing Tongren Eye 
      Center, Capital Medical University, 1 Dongjiaominxiang Road, Beijing, 100073, 
      P.R. China. retina_lw@126.com.
AD  - Beijing Ophthalmology and Visual Sciences Key Laboratory, Capital Medical 
      University, Beijing, 100073, P.R. China. retina_lw@126.com.
LA  - eng
PT  - Journal Article
DEP - 20230523
PL  - England
TA  - BMC Ophthalmol
JT  - BMC ophthalmology
JID - 100967802
RN  - 0 (Biomarkers)
SB  - IM
MH  - Humans
MH  - *Macular Edema
MH  - *Diabetic Retinopathy
MH  - Retrospective Studies
MH  - Eye
MH  - Biomarkers
MH  - *Diabetes Mellitus
PMC - PMC10204334
OTO - NOTNLM
OT  - Anti-VEGF
OT  - Diabetic macular edema
OT  - Optical coherence tomography
COIS- The authors declare that they have no competing interests.
EDAT- 2023/05/24 01:06
MHDA- 2023/05/25 06:42
PMCR- 2023/05/23
CRDT- 2023/05/23 23:53
PHST- 2023/02/19 00:00 [received]
PHST- 2023/05/11 00:00 [accepted]
PHST- 2023/05/25 06:42 [medline]
PHST- 2023/05/24 01:06 [pubmed]
PHST- 2023/05/23 23:53 [entrez]
PHST- 2023/05/23 00:00 [pmc-release]
AID - 10.1186/s12886-023-02973-7 [pii]
AID - 2973 [pii]
AID - 10.1186/s12886-023-02973-7 [doi]
PST - epublish
SO  - BMC Ophthalmol. 2023 May 23;23(1):232. doi: 10.1186/s12886-023-02973-7.